Bharat Biotech International Limited, Genome Valley, Shamirpet, Hyderabad, Telangana, India.
Bharat Biotech International Limited, Genome Valley, Shamirpet, Hyderabad, Telangana, India. Address for correspondence: V Krishna Mohan, Executive Director, Bharat Biotech International Limited, Genome Valley, Shamirpet, Hyderabad, Telangana, India.
Indian Pediatr. 2020 May 15;57(5):407-410. doi: 10.1007/s13312-020-1812-z. Epub 2020 Apr 15.
The world is currently facing an unprecedented global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Predicting the next source of the pandemic can be very challenging. As vaccination is the best way to prevent an infectious disease, the development of an effective vaccine against SARS-CoV-2 can not only reduce the morbidity and mortality associated with it, but can also lessen the economic impact. As the traditional method of vaccine development takes many years for a vaccine to be available to the society, the vaccine development for SARS-CoV-2 should be speeded up using a pandemic approach with fast-track approvals from the regulatory authorities. Various challenges associated with developing a vaccine during the pandemic such as technological hurdles, clinical development pathways, regulatory issues, and support from global funding agencies are expressed here.
目前，世界正面临由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的前所未有的全球大流行。预测下一次大流行的源头极具挑战性。由于接种疫苗是预防传染病的最佳方法，因此开发针对 SARS-CoV-2 的有效疫苗不仅可以降低与之相关的发病率和死亡率，还可以减轻经济影响。由于传统的疫苗开发方法需要多年时间才能将疫苗推向社会，因此应该采用大流行方法来加快 SARS-CoV-2 的疫苗开发，并获得监管机构的快速审批。本文阐述了在大流行期间开发疫苗所面临的各种挑战，例如技术障碍、临床开发途径、监管问题以及全球资金机构的支持。
